1. Home
  2. OSPN vs ZURA Comparison

OSPN vs ZURA Comparison

Compare OSPN & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneSpan Inc.

OSPN

OneSpan Inc.

HOLD

Current Price

$10.55

Market Cap

449.1M

Sector

Technology

ML Signal

HOLD

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$6.27

Market Cap

435.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSPN
ZURA
Founded
1991
2022
Country
United States
United States
Employees
N/A
30
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
449.1M
435.0M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
OSPN
ZURA
Price
$10.55
$6.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
9
Target Price
$16.67
$11.78
AVG Volume (30 Days)
550.2K
457.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.86%
N/A
EPS Growth
28.77
N/A
EPS
1.88
N/A
Revenue
$243,180,000.00
N/A
Revenue This Year
$3.12
N/A
Revenue Next Year
$3.42
N/A
P/E Ratio
$5.69
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.16
$0.99
52 Week High
$18.13
$7.25

Technical Indicators

Market Signals
Indicator
OSPN
ZURA
Relative Strength Index (RSI) 40.58 45.86
Support Level $10.26 $5.62
Resistance Level $11.68 $6.90
Average True Range (ATR) 0.41 0.52
MACD 0.02 -0.06
Stochastic Oscillator 31.75 0.98

Price Performance

Historical Comparison
OSPN
ZURA

About OSPN OneSpan Inc.

OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. Its solutions secure and manage access to digital assets and protect online transactions, via mobile devices and in-person. Authentication and anti-fraud solutions are the organization's primary product offerings and include multifactor authentication and virtual private network access capabilities. The company derives revenues from hardware and license fees, maintenance and support fees, and subscription fees. A large majority of the firm's revenue is generated in Europe, the Middle East, and Africa, and the rest in the United States and Asia-Pacific region.

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Share on Social Networks: